Caribou Biosciences (CRBU) Operating Leases (2022 - 2026)

Caribou Biosciences (CRBU) has 5 years of Operating Leases data on file, last reported at $25.7 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $25.7 million, up 5.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.7 million (up 5.49% YoY), and the FY2025 annual result was $26.0 million, up 3.85% from the prior year.
• Operating Leases retreated to $25.7 million in Q1 2026 per CRBU's latest filing, from $26.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $27.9 million in Q3 2022 and troughed at $22.8 million in Q3 2025.
• A 5-year average of $26.0 million and a median of $26.2 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2025 and 2026: Operating Leases declined 14.5% in 2025, then advanced 5.49% in 2026.
• A 5-year view of Operating Leases shows it stood at $26.8 million in 2022, then dropped by 3.26% to $25.9 million in 2023, then dropped by 3.27% to $25.1 million in 2024, then rose by 3.85% to $26.0 million in 2025, then slipped by 1.41% to $25.7 million in 2026.
• Business Quant data shows CRBU's Operating Leases at $25.7 million in Q1 2026, $26.0 million in Q4 2025, and $22.8 million in Q3 2025.